Head-to-head evidence
CD123 targeted CAR-NK cells vs Tagraxofusp
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Acute Myeloid Leukemia
Shared mechanism: CD123 · full Acute Myeloid Leukemia pipeline
CD123 targeted CAR-NK cells
Developed by Chongqing Precision Biotech Co., Ltd
NCT06006403 · Phase 1/2 · completed
This was a non-randomized, open-label study with no comparator and only five participants. Its primary outcomes included safety and objective response rate, but results are not posted, so whether the primary outcomes were met cannot be determined.
Tagraxofusp
Marketed by Stemline Therapeutics, Inc.
NCT02113982 · Phase 1/2 · completed
The study was non-randomized, open-label, single-arm, and had no comparator; although complete response is a clinical disease outcome, the main efficacy cohort included only 13 patients. Its reported response rate therefore provides limited controlled evidence for tagraxofusp, and no formal between-treatment primary endpoint comparison was applicable.
Next expected readout: April 2027 · NCT06498973 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: CD123 targeted CAR-NK cells's landscape · Tagraxofusp's landscape